Showing results (501-510 of 567) with videos related to
Sort By:
Pageof 57
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.Ebiomedicine|March 10, 2018
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy AdultsL Coughlan, S Sridhar, R Payne, et al.European Urology|April 30, 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialPetros Grivas, Se Hoon Park, Eric Voog, et al.Neuromuscular Disorders : NMD|January 5, 2025
Magnetic resonance imaging in idiopathic inflammatory myopathies: deciphering the pattern of muscle involvementS Sridhar, Saraswati Nashi, Karthik Kulanthaivelu, et al.Cancer Medicine|July 13, 2021
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223Esmail M Al-Ezzi, Husam A Alqaisi, Marco A J Iafolla, et al.Diabetes & Vascular Disease Research|October 20, 2022
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosisElisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, et al.European Urology|June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only DiseaseJoaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.Urologic Oncology|October 30, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.European Urology|July 16, 2019
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic EffectFilippo Pederzoli, Marco Bandini, Alberto Briganti, et al.Pageof 57